71.31
price up icon2.28%   1.5818
 
loading
Insmed Inc stock is traded at $71.31, with a volume of 632.14K. It is up +2.28% in the last 24 hours and down -1.36% over the past month. Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$69.73
Open:
$69.92
24h Volume:
632.14K
Relative Volume:
0.29
Market Cap:
$12.99B
Revenue:
$381.03M
Net Income/Loss:
$-1.01B
P/E Ratio:
-11.99
EPS:
-5.95
Net Cash Flow:
$-789.25M
1W Performance:
+5.61%
1M Performance:
-1.36%
6M Performance:
-1.52%
1Y Performance:
+29.55%
1-Day Range:
Value
$69.59
$71.76
1-Week Range:
Value
$65.56
$71.76
52-Week Range:
Value
$54.71
$84.91

Insmed Inc Stock (INSM) Company Profile

Name
Name
Insmed Inc
Name
Phone
908-977-9900
Name
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Name
Employee
1,271
Name
Twitter
@insmed
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
INSM's Discussions on Twitter

Compare INSM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INSM
Insmed Inc
71.31 12.39B 381.03M -1.01B -789.25M -5.95
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.13 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.66 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.84 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
488.96 65.13B 14.09B 4.50B 2.96B 39.28

Insmed Inc Stock (INSM) Upgrades & Downgrades

Date Action Analyst Rating Change
May-13-25 Initiated Jefferies Buy
Feb-25-25 Initiated RBC Capital Mkts Outperform
Apr-23-24 Initiated Truist Buy
Feb-15-24 Initiated Wolfe Research Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Nov-20-23 Resumed JP Morgan Overweight
Jul-26-23 Initiated Guggenheim Buy
Dec-09-22 Initiated Mizuho Buy
Dec-07-22 Initiated Barclays Overweight
Nov-18-22 Initiated BofA Securities Buy
Apr-27-22 Initiated Goldman Buy
Dec-06-21 Initiated JP Morgan Overweight
Oct-19-21 Resumed Monness Crespi & Hardt Buy
Oct-19-21 Resumed Morgan Stanley Overweight
Oct-08-21 Initiated Cantor Fitzgerald Overweight
Apr-26-21 Resumed Credit Suisse Outperform
Dec-17-20 Initiated Berenberg Buy
Oct-12-20 Resumed Stifel Buy
Sep-03-19 Initiated Goldman Buy
Apr-09-19 Reiterated H.C. Wainwright Buy
Feb-15-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jan-17-19 Upgrade Goldman Neutral → Buy
Jan-02-19 Initiated Canaccord Genuity Buy
Aug-06-18 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-23-18 Initiated Goldman Neutral
Apr-23-18 Upgrade Credit Suisse Neutral → Outperform
Mar-21-18 Initiated Morgan Stanley Overweight
Jan-18-18 Initiated Credit Suisse Neutral
Sep-05-17 Reiterated Evercore ISI Outperform
Aug-17-17 Initiated Evercore ISI Outperform
Jul-11-17 Initiated Robert W. Baird Outperform
Mar-15-16 Initiated Stifel Buy
Nov-09-15 Downgrade UBS Buy → Neutral
Oct-06-15 Reiterated H.C. Wainwright Buy
Jun-09-15 Initiated Citigroup Neutral
Mar-26-14 Reiterated HC Wainwright Buy
View All

Insmed Inc Stock (INSM) Latest News

pulisher
May 28, 2025

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga

May 28, 2025
pulisher
May 28, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Health - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference – Company Announcement - Financial Times

May 28, 2025
pulisher
May 27, 2025

Insmed’s SWOT analysis: rare disease biotech stock shows promise amid challenges - Investing.com

May 27, 2025
pulisher
May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025
pulisher
May 21, 2025

Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Insmed (INSM) Highlights Promising Brensocatib Trial Results at - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Insmed (INSM) Highlights Promising Brensocatib Trial Results at ATS 2025 | INSM Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - Yahoo Finance

May 21, 2025
pulisher
May 20, 2025

Captrust Financial Advisors Sells 631 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World

May 20, 2025
pulisher
May 17, 2025

Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM) - Defense World

May 17, 2025
pulisher
May 16, 2025

HC Wainwright Issues Optimistic Outlook for Insmed Earnings - Defense World

May 16, 2025
pulisher
May 15, 2025

INSMED Executives Sell Shares to Satisfy Tax Obligations - TradingView

May 15, 2025
pulisher
May 15, 2025

Jefferies Financial Group Initiates Coverage on Insmed (NASDAQ:INSM) - Defense World

May 15, 2025
pulisher
May 14, 2025

Jefferies Initiates Coverage of Insmed (BIT:1INSM) with Buy Recommendation - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Jefferies Initiates Coverage of Insmed (BMV:INSM) with Buy Recommendation - Nasdaq

May 14, 2025
pulisher
May 13, 2025

Jefferies sets $105 target on Insmed stock with Buy rating By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Insmed at Bank of America 2025 Healthcare Conference: Strategic Pipeline Focus - Investing.com

May 13, 2025
pulisher
May 13, 2025

Jefferies Initiates Coverage on INSM with a Buy Rating and $105 PT | INSM Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Jefferies Initiates Coverage of Insmed (LSE:0JAV) with Buy Recommendation - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

May 13, 2025
pulisher
May 13, 2025

Jefferies Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Jefferies sets $105 target on Insmed stock with Buy rating - Investing.com

May 13, 2025
pulisher
May 13, 2025

Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - Defense World

May 13, 2025
pulisher
May 12, 2025

Insmed (INSM) Gains Buy Rating from Jefferies with Promising Out - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Insmed (INSM) Receives Reaffirmed Buy Rating from HC Wainwright - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Analyst Expectations For Insmed's Future - Benzinga

May 12, 2025
pulisher
May 12, 2025

Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of “Buy” by Analysts - Defense World

May 12, 2025
pulisher
May 12, 2025

UBS Group Cuts Insmed (NASDAQ:INSM) Price Target to $109.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 12, 2025
pulisher
May 11, 2025

Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results - Yahoo Finance

May 11, 2025
pulisher
May 10, 2025

Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 09, 2025

Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus

May 09, 2025
pulisher
May 09, 2025

UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - TradingView

May 09, 2025
pulisher
May 09, 2025

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga

May 09, 2025
pulisher
May 09, 2025

Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Insmed: Q1 Earnings Snapshot - Greenwich Time

May 09, 2025
pulisher
May 09, 2025

Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Insmed’s Earnings Call: Strong Growth and Optimistic Outlook - TipRanks

May 08, 2025
pulisher
May 08, 2025

Insmed Q1 2025 Earnings Call Transcript - MarketBeat

May 08, 2025
pulisher
May 08, 2025

Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com

May 08, 2025
pulisher
May 08, 2025

Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus

May 08, 2025

Insmed Inc Stock (INSM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$305.23
price down icon 0.07%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
Cap:     |  Volume (24h):